Aurobindo Pharma Ltd.

Feb 25, 2021 17:02 Source: BSE

Aurobindo Pharma - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 25, 2021 for RPR Sons Advisors Pvt Ltd, P Suneela Rani (Jointly holding)

Feb 25, 2021 10:29 Source: BSE

Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Please refer to our letter dated February 9, 2021 wherein we have intimated the schedule of Investors/ Analysts call on February 11, 2021. We are attaching herewith the Transcript of the analyst / investor call on the Un-audited Financial Results of the Company for the third quarter and nine months period ended December 31, 2020 and the same is being uploaded on the website of the Company and is available in the following web link. https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/

Feb 23, 2021 17:23 Source: BSE

Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Acquisition

We would like to inform that the Company has entered into binding agreements to invest Rs.5.382 Crores each in NVNR (Ramannapet I) Power Plant Private Limited and NVNR (Ramannapet II) Power Plant Private Limited, Hyderabad based solar power generating companies, aggregating to Rs. 10.764 Crores (Rupees ten crores seventy six lakhs forty thousand) by subscribing to additional equity shares and/or other securities of the said solar power generating companies to avail the benefit of captive consumption of Solar Power. After making the said investments, the Company will be holding 26% of the share capital in each of the aforesaid solar power generating companies. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is enclosed as 'Annexure I'.

Feb 19, 2021 11:07 Source: BSE

Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

We enclose a copy of the Press Release that is being issued by the Company in connection with USFDA approval received by the Company for Droxidopa Capsules.

Feb 17, 2021 17:20 Source: BSE

Aurobindo Pharma - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 17, 2021 for Axis Clinicals Ltd, Trident Chemphar Ltd, RPR Sons Advisors Pvt Ltd (Jointly holding)

Feb 11, 2021 16:39 Source: BSE

Aurobindo Pharma - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 11, 2021 for RPR Sons Advisors Pvt Ltd & P. Suneela Rani (Jointly holding)

Feb 10, 2021 19:21 Source: BSE

Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Investor Presentation

Please refer to our letter dated February 9, 2021 wherein we have intimated the schedule of Investors/ Analysts call on February 11, 2021. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the third Quarter ended December 31, 2020. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/results-announcements/

Feb 10, 2021 19:10 Source: BSE

Aurobindo Pharma - Record Date For The Third Interim Dividend 2020-21

The Board of Directors of the Company at its meeting held today, February 10, 2021, has, inter alia, considered and approved a Third Interim Dividend @ 150% i.e Rs.1.50 (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2020-21. The Company has fixed February 23, 2021 as the Record Date for the purpose of payment of Third Interim Dividend and the same will be paid on or before March 4, 2021.

Feb 10, 2021 19:07 Source: BSE

Aurobindo Pharma - Corporate Action-Board approves Dividend

The Board of Directors of the Company at its meeting held today, February 10, 2021, has, inter alia, considered and approved a Third Interim Dividend @ 150% i.e Rs.1.50 (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2020-21. The Company has fixed February 23, 2021 as the Record Date for the purpose of payment of Third Interim Dividend and the same will be paid on or before March 4, 2021.

Feb 10, 2021 19:03 Source: BSE

Aurobindo Pharma - Un-Audited Financial Results Of The Company For The Third Quarter And Nine Months Period Ended December 31, 2020

The Board of Directors of the Company at its meeting held today, February 10, 2021, has, inter alia, considered and approved:- 1. the Un-audited Financial Results of the Company for the Third Quarter and nine months period ended December 31, 2020 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company. 2. a Third Interim Dividend @ 150% i.e Rs.1.50 (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2020-21. The Company has fixed February 23, 2021 as the Record Date for the purpose of payment of Third Interim Dividend and the same will be paid on or before March 4, 2021. The Board meeting commenced at 4.00 p.m. and concluded at 6.40 p.m